rVA576
AK701
Phase 2 small_molecule terminated
Quick answer
rVA576 for Keratoconjunctivitis, Atopic is a Phase 2 program (small_molecule) at Akari Therapeutics Plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Akari Therapeutics Plc
- Indication
- Keratoconjunctivitis, Atopic
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated